entertainment -WSS

entertainment

author：focus 2025-09-30 13:14:03 - browse：7

Yichuan Cao/Sipa USA via AP Images

Gilead Sciences said Monday that Trodelvy, its “smart-bomb” medicine that combines an antibody with chemotherapy, did not significantly extend the lives of patients with metastatic non-small cell lung cancer when given after a first treatment failed.

The result, from a closely watched study called Evoke-01, will be seen as a disappointment by investors and oncologists alike.

Drugs like Trodelvy, known as antibody drug conjugates, are one of the hottest areas in oncology. The idea is that these medicines combine an antibody, which is triggered when it binds to a protein on a cancer cell, with a “payload” of chemotherapy that poisons the cancer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

WSS

Trump team launching legal defense fund to help pay legal bills

Gene therapy has helped boys walk. Can scientists keep it that way?

New guidelines on severe brain injury complicate already difficult decisions

The science behind Janet Jackson's pregnancy at 49

A pollution tax on older cars can be extended to London's suburbs after a British court ruling

Sudan conflict brings new atrocities to Darfur as militias kill, rape, burn homes in rampages

leisure time

entertainment

Wikipedia

Trump demands the U.S. pay no more for drugs than other countries … again

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

Medicare details structure of new drug price negotiation program

The science behind Janet Jackson's pregnancy at 49

As demand for Covid shots wanes, Moderna seeks its next success

5 wounded, 2 critically, in Michigan shopping center shooting

What does generative AI mean for health care? We asked experts

The story of mRNA: From a loose idea to a tool that may help curb Covid

BioMarin wins approval for gene therapy to treat hemophilia A

Teacher posts viral 'school supply rant' with advice for parents

knowledge

Gene therapy has helped boys walk. Can scientists keep it that way?

With FDA staff opposed to Sarepta therapy, top official intervened

Philippine ferry was overloaded when it flipped over, leaving 27 dead, official says

Disclosing genetic information: not as worrisome as once feared

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

In areas with more Black doctors, Black people live longer

Wikipedia

hotspot

focus

hotspot